Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer

This study is looking at whether a certain type of protein found in the blood (a glycoprotein) can predict how well immunotherapy will work for people with advanced lung cancer. Researchers will measure this protein before and after treatment to see if it helps forecast patient outcomes. **You may be eligible if...** - You have been diagnosed with advanced non-small cell lung cancer (NSCLC) - You are currently receiving immunotherapy (a PD-1 or PD-L1 inhibitor) - You are in generally good physical condition and able to carry out normal activities - You have at least one measurable tumor on imaging - You are able to provide blood samples before and after treatment - Your life expectancy is at least 12 weeks **You may NOT be eligible if...** - You are unable to provide blood samples as required - Your organ function (blood counts, liver, kidneys) is not adequate - You are unable to give informed consent Talk to your doctor to see if this trial is right for you.